JW Pharmaceutical Overview
Get informed when a big investor buys or sells
+ Follow24.71%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for 001067.KS is 24.71%. That is above the sector sector average of 11.67%. Investors often review this figure alongside JW Pharmaceutical's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, 001067.KS currently prints 24.71% for ROE, while the sector average sits near 11.67%. That is roughly 111.8% above the sector mean. Large gaps often invite a closer look at JW Pharmaceutical's growth, margins, and balance sheet.
Return on Equity shows how effectively JW Pharmaceutical converts resources into returns. At 24.71%, 001067.KS may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting 001067.KS's ROE (24.71%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
